Gainers

• Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million.
• Onconetix (NASDAQ:ONCO) stock rose 6.85% to $0.97. The market value of their outstanding shares is at $3.9 million.
• Vogenx (NASDAQ:VOGX) stock rose 6.52% to $25.78. The market value of their outstanding shares is at $399.0 million.
• PRF Technologies (NASDAQ:PRFX) stock rose 5.89% to $1.04. The market value of their outstanding shares is at $3.4 million.
• Jupiter Neurosciences (NASDAQ:JUNS) stock rose 5.71% to $3.05. The market value of their outstanding shares is at $3.9 million.
• Valion Bio (NASDAQ:VBIO) stock moved upwards by 5.45% to $3.67. The company's market cap stands at $2.4 million.

Losers

• Senti Biosciences (NASDAQ:SNTI) shares declined by 17.1% to $0.28 during Thursday's after-market session. The company's market cap stands at $10.5 million.
• BGM Group (NASDAQ:BGM) shares decreased by 6.62% to $0.23. The market value of their outstanding shares is at $102.1 million.
• Lexaria Bioscience (NASDAQ:LEXX) stock fell 6.53% to $3.15. The market value of their outstanding shares is at $6.8 million.
• Bullfrog AI Hldgs (NASDAQ:BFRG) shares declined by 5.28% to $0.72. The market value of their outstanding shares is at $17.6 million.
• Kala Bio (NASDAQ:KALA) stock decreased by 5.08% to $0.53. The company's market cap stands at $10.8 million.
• IN8bio (NASDAQ:INAB) shares decreased by 5.05% to $1.13. The market value of their outstanding shares is at $10.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.